Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

FDARegulator guidanceBioequivalenceMedicinesHigh confidenceLast verified October 4, 2026

FDA BE guidance for ANDAs (PK endpoints)

Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA

Current edition

May 2026

About this standard

Gives recommendations to generic drug applicants on bioequivalence studies that use pharmacokinetic measures, including study design, subjects, fasting and fed conditions and analysis.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

No market listing is published yet.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube